Mirikizumab Improves Quality of Life in Moderately-to-Severely Active UC: Improvement in IBDQ Scores in Participants of LUCENT-1 and LUCENT-2 Randomized, Double-Blind, Placebo-Controlled Phase 3 Trials

Category Primary study
JournalAmerican Journal of Gastroenterology
Year 2022
This article has no abstract
Epistemonikos ID: 38f5ed4281b66407462f793f7f1aa9414c9601f0
First added on: Feb 15, 2025